Russian Research Center of Radiology and Surgical Technologies (RRCRST) of Ministry of Public Health, Saint-Petersburg, Russia.
Institute for Nuclear Research of Russian Academy of Sciences (INR RAS), Moscow, Russia.
Brain Behav. 2019 Mar;9(3):e01212. doi: 10.1002/brb3.1212. Epub 2019 Feb 6.
The applicability of "Rubidium Chloride, Rb from Generator" radiopharmaceutical for brain tumors (BT) diagnostics is demonstrated on the basis of the application experience of the radiopharmaceutical in neurooncology.
A total of 21 patients with various brain tumors and nonneoplastic abnormal brain masses were investigated.
The results of the imaging and differential diagnostics of malignant and benign tumors, nonneoplastic abnormal brain masses and lesions revealed the prevalence of high uptake of the radiopharmaceutical in the malignant tumors in comparison with benign glioma and arteriovenous malformations in which Rb-chloride accumulates in the vascular phase but does not linger further. The ultra-short half-life of radionuclide Rb (76 s) along with a low absorbed radiation dose with Rb-chloride by intravenous administration create a new possibility of successive use of two or more radiopharmaceuticals for the examination of the same patient. For instance, PET examination with F-FDG, C-methionine, C-choline, or any other radiopharmaceutical can be carried out in just 7-15 min. after Rb-chloride injection.
Research demonstrated an effectiveness of Rb-chloride application as a diagnostic agent in neurooncology. A method of dosing and administration of the generator-produced radiopharmaceutical has been worked out. It is possible to do up to 600 PET sessions using one Russian Rb generator GR-01. The generator is proved to be reliable and easy to use. The interest in Rb-chloride as a tumor-seeking radiopharmaceutical rose due to the active application of the modern devices PET/CT in the routine clinical practice.
基于放射性药物在神经肿瘤学中的应用经验，展示了“氯化铷，发生器中的 Rb”放射性药物在脑肿瘤（BT）诊断中的适用性。
共对 21 例各种脑肿瘤和非肿瘤性异常脑肿块患者进行了研究。
对恶性和良性肿瘤、非肿瘤性异常脑肿块和病变的成像和鉴别诊断结果表明，与良性神经胶质瘤和动静脉畸形相比，放射性药物在恶性肿瘤中的摄取更为普遍，后者在血管期积累 Rb-氯化物，但不会进一步滞留。放射性核素 Rb（76 s）的超短半衰期以及静脉注射 Rb-氯化物时吸收的低辐射剂量为连续使用两种或更多放射性药物对同一患者进行检查创造了新的可能性。例如，在注射 Rb-氯化物后仅 7-15 分钟即可进行 F-FDG、C-蛋氨酸、C-胆碱或任何其他放射性药物的 PET 检查。
研究证明了 Rb-氯化物在神经肿瘤学中作为诊断剂的有效性。已经制定了放射性药物的剂量和给药方法。使用一台俄罗斯 Rb 发生器 GR-01 可以进行多达 600 次 PET 检查。该发生器被证明可靠且易于使用。由于现代 PET/CT 设备在常规临床实践中的广泛应用，对 Rb-氯化物作为一种寻找肿瘤的放射性药物的兴趣增加了。
